logo
ProjectCompleted

Granules III

Completed · India

Source: International Finance Corporation (IFC)

Granules India Limited (“Granules” or the “Company”) – an existing IFC client - is an Indian pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs) of a variety of drugs, including over-the-counter ones. The Company sells its products mainly in the US, Europe, Latin America and Indi

Status
Closed
Sector
Water Supply and Storage, Hospital, Manufacturing (Industrial), Commercial, Waste Processing and Treatment, Warehouse, Government
Location
India
Updated
22 Jul 2026
Source
International Finance Corporation (IFC)

ConstructChat

Ask ConstructChat about Granules III

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

5 Q
The project “Granules III” is an infrastructure initiative in the Water Supply and Storage sector, located in India. Taiyo aggregates data on it from International Finance Corporation (IFC).

Participants

Sponsoring Agency

Status

Original status

completed

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Granules India Limited (“Granules” or the “Company”) – an existing IFC client - is an Indian pharmaceutical company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs) of a variety of drugs, including over-the-counter ones. The Company sells its products mainly in the US, Europe, Latin America and India. Granules has wholly-owned manufacturing plants near Hyderabad in India (Jeedimetla, Bonthapally, and Gagillapur) and in Vishakhapatnam, India along with a R&D and manufacturing facility in Virginia, USA Further, through its joint ventures, it   has one plant in China and yet another manufacturing plant in Vishakhapatnam, India. . The Company is undertaking an investment program directed towards setting up new capacity, expanding existing capacities and investing in R&D to improve its product mix in favor of higher value-added products. A large part of the investment program is in the form of capital expenditures in India (the “Project”), which is estimated to cost about US$84 million. The Project includes building a greenfield API manufacturing facility in Vishakhapatnam, India, expanding existing API and PFI capacities, investment in R&D, quality assurance ("QA”), and quality control("QC”), investment  in other general capital expenditures at existing facilities,  and additional warehouse capacity.

Original sector

G-FA - Pharmaceuticals and Medicine

Budget

Location

Country

India

Source

Source

International Finance Corporation (IFC)

URL

More Details

Record type

Project

Sector

Water Supply and Storage, Hospital, Manufacturing (Industrial), Commercial, Waste Processing and Treatment, Warehouse, Government

Article published date

2025-10-16

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project